immatics biotechnologies GmbH Stock News

Immatics NV shares IMTX, -2.87% gained more than 6% premarket on Monday after the company announced a collaboration with Moderna Inc. MRNA, -0.66% to research and develop new cancer therapies. The par

Vaccine maker Moderna said on Monday it had struck a deal with Immatics for developing cancer vaccines and therapies and would pay the drug developer $120 million in cash and additional milestone paym

Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules Companies to leverage Immatics' XPRESIDENT® target discovery platform and Moderna'

The consensus price target hints at a 45.8% upside potential for Immatics (IMTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate

Immatics (IMTX) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.23 per share a year ago.

Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in

Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in

A number of VBR "green energy" picks have popped higher in January, pulling investment returns for the group of past picks strongly higher. A performance review of 46 previous selections since late Ju

Immatics (IMTX) delivered earnings and revenue surprises of -3.23% and 13.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Source: CI Photos / Shutterstock.com Immatics (NASDAQ: IMTX ) stock is climbing higher on Monday after the clinical-stage biopharmaceutical company revealed details of an underwritten public offering.

Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Immatics N.V. (NASDAQ:IMTX) is currently valued at $7.55.

Bristol Myers (BMY) strengthens its partnership with the small biotech company Immatics (IMTX) to develop multiple allogenic cell therapies targeting multiple cancer indications.

Immatics (IMTX) delivered earnings and revenue surprises of -18.28% and 23.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?